vs

Side-by-side financial comparison of Designer Brands Inc. (DBI) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Designer Brands Inc. is the larger business by last-quarter revenue ($752.4M vs $622.0M, roughly 1.2× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 2.4%, a 32.0% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs -3.2%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -0.1%).

Designer Brands Inc. is an American company that sells designer and name brand shoes and fashion accessories. It owns the Designer Shoe Warehouse (DSW) store chain, and operates over 500 stores in the United States and an e-commerce website.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

DBI vs RPRX — Head-to-Head

Bigger by revenue
DBI
DBI
1.2× larger
DBI
$752.4M
$622.0M
RPRX
Growing faster (revenue YoY)
RPRX
RPRX
+8.0% gap
RPRX
4.8%
-3.2%
DBI
Higher net margin
RPRX
RPRX
32.0% more per $
RPRX
34.4%
2.4%
DBI
Faster 2-yr revenue CAGR
RPRX
RPRX
Annualised
RPRX
4.6%
-0.1%
DBI

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
DBI
DBI
RPRX
RPRX
Revenue
$752.4M
$622.0M
Net Profit
$18.2M
$214.2M
Gross Margin
45.1%
Operating Margin
5.7%
62.4%
Net Margin
2.4%
34.4%
Revenue YoY
-3.2%
4.8%
Net Profit YoY
40.0%
2.9%
EPS (diluted)
$0.35
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DBI
DBI
RPRX
RPRX
Q4 25
$752.4M
$622.0M
Q3 25
$739.8M
$609.3M
Q2 25
$686.9M
$578.7M
Q1 25
$713.6M
$568.2M
Q4 24
$777.2M
$593.6M
Q3 24
$771.9M
$564.7M
Q2 24
$746.6M
$537.3M
Q1 24
$754.3M
$568.0M
Net Profit
DBI
DBI
RPRX
RPRX
Q4 25
$18.2M
$214.2M
Q3 25
$10.8M
$288.2M
Q2 25
$-17.4M
$30.2M
Q1 25
$-38.2M
$238.3M
Q4 24
$13.0M
$208.2M
Q3 24
$13.8M
$544.0M
Q2 24
$783.0K
$102.0M
Q1 24
$-29.6M
$4.8M
Gross Margin
DBI
DBI
RPRX
RPRX
Q4 25
45.1%
Q3 25
43.7%
Q2 25
43.0%
Q1 25
75.7%
Q4 24
43.0%
Q3 24
44.0%
Q2 24
44.2%
Q1 24
38.8%
Operating Margin
DBI
DBI
RPRX
RPRX
Q4 25
5.7%
62.4%
Q3 25
3.6%
70.1%
Q2 25
-1.1%
36.3%
Q1 25
-3.6%
94.0%
Q4 24
2.9%
60.9%
Q3 24
3.7%
Q2 24
1.3%
50.2%
Q1 24
-4.8%
-13.0%
Net Margin
DBI
DBI
RPRX
RPRX
Q4 25
2.4%
34.4%
Q3 25
1.5%
47.3%
Q2 25
-2.5%
5.2%
Q1 25
-5.3%
41.9%
Q4 24
1.7%
35.1%
Q3 24
1.8%
96.3%
Q2 24
0.1%
19.0%
Q1 24
-3.9%
0.8%
EPS (diluted)
DBI
DBI
RPRX
RPRX
Q4 25
$0.35
$0.49
Q3 25
$0.22
$0.67
Q2 25
$-0.36
$0.07
Q1 25
$-0.69
$0.55
Q4 24
$0.24
$0.46
Q3 24
$0.24
$1.21
Q2 24
$0.01
$0.23
Q1 24
$-899.54
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DBI
DBI
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$51.4M
$618.7M
Total DebtLower is stronger
$463.1M
$9.0B
Stockholders' EquityBook value
$298.6M
$9.7B
Total Assets
$2.1B
$19.6B
Debt / EquityLower = less leverage
1.55×
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DBI
DBI
RPRX
RPRX
Q4 25
$51.4M
$618.7M
Q3 25
$44.9M
$938.9M
Q2 25
$46.0M
$631.9M
Q1 25
$44.8M
$1.1B
Q4 24
$36.2M
$929.0M
Q3 24
$38.8M
$950.1M
Q2 24
$43.4M
$1.8B
Q1 24
$49.2M
$843.0M
Total Debt
DBI
DBI
RPRX
RPRX
Q4 25
$463.1M
$9.0B
Q3 25
$509.6M
$8.9B
Q2 25
$516.2M
$8.0B
Q1 25
$484.3M
$7.6B
Q4 24
$529.6M
$7.6B
Q3 24
$459.0M
$7.6B
Q2 24
$469.3M
$7.6B
Q1 24
$420.3M
$6.1B
Stockholders' Equity
DBI
DBI
RPRX
RPRX
Q4 25
$298.6M
$9.7B
Q3 25
$280.8M
$9.6B
Q2 25
$266.9M
$9.5B
Q1 25
$278.5M
$9.8B
Q4 24
$318.5M
$10.3B
Q3 24
$355.5M
$10.3B
Q2 24
$358.5M
$9.8B
Q1 24
$359.2M
$9.9B
Total Assets
DBI
DBI
RPRX
RPRX
Q4 25
$2.1B
$19.6B
Q3 25
$2.1B
$19.3B
Q2 25
$2.1B
$18.3B
Q1 25
$2.0B
$17.6B
Q4 24
$2.1B
$18.2B
Q3 24
$2.1B
$18.0B
Q2 24
$2.2B
$17.7B
Q1 24
$2.1B
$16.1B
Debt / Equity
DBI
DBI
RPRX
RPRX
Q4 25
1.55×
0.92×
Q3 25
1.81×
0.93×
Q2 25
1.93×
0.84×
Q1 25
1.74×
0.78×
Q4 24
1.66×
0.74×
Q3 24
1.29×
0.74×
Q2 24
1.31×
0.78×
Q1 24
1.17×
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DBI
DBI
RPRX
RPRX
Operating Cash FlowLast quarter
$66.5M
$827.1M
Free Cash FlowOCF − Capex
$57.5M
FCF MarginFCF / Revenue
7.6%
Capex IntensityCapex / Revenue
1.2%
Cash ConversionOCF / Net Profit
3.65×
3.86×
TTM Free Cash FlowTrailing 4 quarters
$99.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DBI
DBI
RPRX
RPRX
Q4 25
$66.5M
$827.1M
Q3 25
$21.4M
$702.6M
Q2 25
$-20.4M
$364.0M
Q1 25
$70.1M
$596.1M
Q4 24
$-9.8M
$742.5M
Q3 24
$41.6M
$703.6M
Q2 24
$-19.7M
$658.2M
Q1 24
$-40.1M
$664.6M
Free Cash Flow
DBI
DBI
RPRX
RPRX
Q4 25
$57.5M
Q3 25
$11.9M
Q2 25
$-27.6M
Q1 25
$58.1M
Q4 24
$-19.2M
Q3 24
$28.0M
Q2 24
$-35.6M
Q1 24
$-52.8M
FCF Margin
DBI
DBI
RPRX
RPRX
Q4 25
7.6%
Q3 25
1.6%
Q2 25
-4.0%
Q1 25
8.1%
Q4 24
-2.5%
Q3 24
3.6%
Q2 24
-4.8%
Q1 24
-7.0%
Capex Intensity
DBI
DBI
RPRX
RPRX
Q4 25
1.2%
Q3 25
1.3%
Q2 25
1.1%
Q1 25
1.7%
Q4 24
1.2%
Q3 24
1.8%
Q2 24
2.1%
Q1 24
1.7%
Cash Conversion
DBI
DBI
RPRX
RPRX
Q4 25
3.65×
3.86×
Q3 25
1.98×
2.44×
Q2 25
12.06×
Q1 25
2.50×
Q4 24
-0.75×
3.57×
Q3 24
3.01×
1.29×
Q2 24
-25.13×
6.45×
Q1 24
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DBI
DBI

Womens$280.7M37%
Athletic Footwear$188.6M25%
Wholesale$89.8M12%
Canada Retail Segment$77.3M10%
Mens$76.1M10%
Kids$24.2M3%
Commission Income$10.8M1%
Directto Consumer$1.3M0%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons